MSB 3.21% $1.13 mesoblast limited

Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD, page-82

  1. 5,838 Posts.
    lightbulb Created with Sketch. 2110
    "Mesoblast will provide these new data to OTAT and address other remaining CRL items as required for the BLA resubmission."

    There is nothing in the announcement that says another meeting will be necessary.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.